Literature DB >> 20447551

Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.

Hsin-Hsin Tsao1, Kun-Ju Lin, Jyuhn-Huarng Juang, Daniel M Skovronsky, Tzu-Chen Yen, Shiaw-Pyng Wey, Mei-Ping Kung.   

Abstract

UNLABELLED: The vesicular monoamine transporter type 2 (VMAT2) is highly expressed in pancreatic beta-cells and thus has been proposed to be a potential target for measuring beta-cell mass (BCM) by molecular imaging. C-11- and F-18-labeled tetrabenazine derivatives targeting VMAT2 have shown some promising results as potential biomarkers for BCM. In the present study, we examined the binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine ([(18)F]AV-133), a potential PET tracer for BCM imaging, in rat pancreas and rat brain.
METHODS: Pancreatic exocrine cells and pancreatic islet cells were isolated and purified from Sprague-Dawley rats. Membrane homogenates, prepared from both pancreatic exocrine and islet cells as well as from brain striatum and hypothalamus regions, were used for in vitro binding studies. In vitro and ex vivo autoradiography studies with [(18)F]AV-133 were performed on rat brain and rat pancreas sections. Immunohistochemistry studies were performed to confirm the distribution of VMAT2 on islet beta-cells.
RESULTS: Excellent binding affinities of [(18)F]AV-133 were observed in rat striatum and hypothalamus homogenates with K(d) values of 0.19 and 0.25 nM, respectively. In contrast to single-site binding observed in rat striatum homogenates, rat islet cell homogenates showed two saturable binding sites (site A: K(d)=6.76 nM, B(max)=60 fmol/mg protein; site B: K(d)=241 nM, B(max)=1500 fmol/mg protein). Rat exocrine pancreas homogenates showed only a single low-affinity binding site (K(d)=209 nM), which was similar to site B in islet cells. In vitro autoradiography of [(18)F]AV-133 using frozen sections of rat pancreas showed specific labeling of islets, as evidenced by co-localization with anti-insulin antibody. Ex vivo VMAT2 pancreatic autoradiography in the rat, however, was not successful, in contrast to the excellent ex vivo autoradiography of VMAT2 binding sites in the brain. In vivo/ex vivo islet labeling may be complicated by the presence of the low-affinity/high-capacity site B binding in rat pancreas.
CONCLUSIONS: [(18)F]AV-133 is an excellent imaging agent for mapping VMAT2 sites in rat brain and specifically binds rat islet cells in vitro and postmortem. Additional optimization may be required to achieve ex vivo islet beta-cell labeling in rats. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447551     DOI: 10.1016/j.nucmedbio.2010.01.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  13 in total

1.  Multimodal image coregistration and inducible selective cell ablation to evaluate imaging ligands.

Authors:  John Virostko; Joseph Henske; Laurent Vinet; Smaragda Lamprianou; Chunhua Dai; Aramandla Radhika; Ronald M Baldwin; Mohammad S Ansari; Franz Hefti; Daniel Skovronsky; Hank F Kung; Pedro L Herrera; Todd E Peterson; Paolo Meda; Alvin C Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  Imaging the islet graft by positron emission tomography.

Authors:  Olof Eriksson; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

Review 3.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

Review 4.  Beta-cell imaging: call for evidence-based and scientific approach.

Authors:  Björn A Blomberg; Ion Codreanu; Gang Cheng; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

5.  An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [18F]FP-(+)-DTBZ.

Authors:  Chao Zhao; Chunyi Liu; Jie Tang; Yingjiao Xu; Minhao Xie; Zhengping Chen
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

6.  In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.

Authors:  Marc D Normandin; Kitt F Petersen; Yu-Shin Ding; Shu-Fei Lin; Sarita Naik; Krista Fowles; Daniel M Skovronsky; Kevan C Herold; Timothy J McCarthy; Roberto A Calle; Richard E Carson; Judith L Treadway; Gary W Cline
Journal:  J Nucl Med       Date:  2012-05-09       Impact factor: 10.057

7.  Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET.

Authors:  Mahabuba Jahan; Olof Eriksson; Peter Johnström; Olle Korsgren; Anders Sundin; Lars Johansson; Christer Halldin
Journal:  EJNMMI Res       Date:  2011-12-05       Impact factor: 3.138

8.  Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.

Authors:  Matthew J Freeby; Patricia Kringas; Robin S Goland; Rudolph L Leibel; Antonella Maffei; Chaitan Divgi; Masanori Ichise; Paul E Harris
Journal:  Mol Imaging Biol       Date:  2015-09-14       Impact factor: 3.488

9.  Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET.

Authors:  Kun-Ju Lin; Yi-Hsin Weng; Chia-Ju Hsieh; Wey-Yil Lin; Shiaw-Pyng Wey; Mei-Ping Kung; Tzu-Chen Yen; Chin-Song Lu; Ing-Tsung Hsiao
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

Review 10.  The β Cell in Diabetes: Integrating Biomarkers With Functional Measures.

Authors:  Steven E Kahn; Yi-Chun Chen; Nathalie Esser; Austin J Taylor; Daniël H van Raalte; Sakeneh Zraika; C Bruce Verchere
Journal:  Endocr Rev       Date:  2021-09-28       Impact factor: 25.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.